Definium Therapeutics (DFTX) Operating Expenses (2019 - 2026)

Definium Therapeutics (DFTX) has 8 years of Operating Expenses data on file, last reported at $59.2 million in Q1 2026.

• Quarterly Operating Expenses rose 84.15% year-over-year to $59.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $193.4 million (up 69.81% YoY) and the FY2025 annual result came in at $166.3 million, up 60.04% from the prior year.
• Operating Expenses rose to $59.2 million in Q1 2026 per DFTX's latest filing, from $47.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $59.2 million in Q1 2026 and bottomed at $13.9 million in Q4 2022.
• The 5-year median for Operating Expenses is $24.5 million (2024), against an average of $28.8 million.
• The widest annual swing landed in 2022, when Operating Expenses plunged 62.53%; it then jumped 84.21% in 2025.
• Tracing DFTX's Operating Expenses over 5 years: stood at $13.9 million in 2022, then soared by 59.75% to $22.2 million in 2023, then soared by 46.19% to $32.5 million in 2024, then surged by 46.57% to $47.6 million in 2025, then increased by 24.47% to $59.2 million in 2026.
• Per Business Quant, the three latest DFTX Operating Expenses figures stand at $59.2 million (Q1 2026), $47.6 million (Q4 2025), and $45.7 million (Q3 2025).

Peer Comparison